对HNSCC的新陈代谢和转录基因分析确定了AMIGO2作为调节瘤微环境的治疗标
Gan Liu1,2, Xinfeng Yao3, Yuchen Hou4
1Department of Stomatology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
NPJ precision oncology
|November 18, 2025
概括
这项研究揭示了头部和部状细胞癌 (HNSCC) 的代谢异质性,确定纯素代谢是关键. 向AMIGO2增强了HNSCC患者的免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 免疫治疗是一种免疫疗法.
背景情况:
- 代谢重编程与瘤微环境有关.
- 头部和部状细胞癌 (HNSCC) 提出了复杂的代谢挑战.
研究的目的:
- 为了描述HNSCC的代谢景观.
- 在HNSCC中确定预后生物标志物和治疗点.
主要方法:
- 空间代谢学/转录学
- 单细胞转录组学 单细胞转录组学
- 批量多主题分析.
- 基于基受体的签名 (LRS) 的发展发展.
- 在体外和体内实验实验.
主要成果:
- 在HNSCC中确定了代谢异质性,具有丰富的纯素代谢.
- 开发了一个与NT5E相关的LRS作为一个独立的预后指标.
- 低LRS亚型与增加的免疫透和更好的免疫治疗反应相关.
- 降低AMIGO2的调节抑制了瘤的入侵/迁移,并促进了免疫透.
- 结合AMIGO2向和抗PD-1疗法显示出更高的疗效.
结论:
- 艾米戈2是HNSCC纯素代谢和瘤进展的关键调节者.
- 针对AMIGO2与免疫疗法相结合,为HNSCC提供了一个有前途的治疗策略.
- 这些发现在临床HNSCC和前发病队列中得到了验证.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K


